Xilio Therapeutics (XLO) Other financing activities (2020 - 2026)

Xilio Therapeutics has disclosed Other financing activities across 7 years of filings, most recently posting $35000.0 for Q2 2026.

• In Q2 2026, Other financing activities changed 0.0% year-over-year to $35000.0; the TTM figure through Jun 2026 stood at $35.8 million (up 48310.81% YoY), while the FY2025 annual figure was $35.8 million, up 52588.24% from the prior year.
• Other financing activities came in at $35000.0 for Q2 2026 at Xilio Therapeutics, up from $1000.0 in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $35.8 million in Q4 2025 to a low of -$14.6 million in Q2 2024.
• Average Other financing activities over 5 years is $2.6 million, with a median of $34500.0 recorded in 2024.
• The largest YoY upside for Other financing activities was 105158.82% in 2025 against a maximum downside of 99.88% in 2025.
• Over 5 years, Other financing activities stood at $16000.0 in 2022, then surged by 237.5% to $54000.0 in 2023, then plunged by 37.04% to $34000.0 in 2024, then soared by 105158.82% to $35.8 million in 2025, then plunged by 99.9% to $35000.0 in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were $35000.0 in Q2 2026, $1000.0 in Q1 2026, and $35.8 million in Q4 2025.